Tenax Therapeutics

Tenax Therapeutics, Inc., is a pharmaceutical company. It focuses on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The firm owns the North American rights to develop and commercialize levosimendan and has recently released data regarding its Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces Levosimendan in PH-HFpEF webinar on Aug. 16th at 10 am, with Drs. Daniel Burkhoff & Stuart Rich.

Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

New York, New York--(Newsfile Corp. - July 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/tenax-therapeutics-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces retirement of CEO Anthony A. DiTonno, Christopher T. Giordano as new CEO and $10 million PIPE.

Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

The stock price of Tenax Therapeutics Inc (NASDAQ: TENX) increased by over 12% pre-market. This is why it happened.

TENX Stock Price Increases Over 12% Pre-Market: Why It Happened

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces inclusion in the Russell Microcap® Index after the U.S. market opens on June 28, 2021

Tenax Therapeutics Set to Join Russell Microcap® Index

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces first quarter 2021 financial results and provides business update.

Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

The stock price of Tenax Therapeutics (NASDAQ: TENX) increased by over 35% during intraday trading. This is why it happened.

Tenax Therapeutics Stock Price Increased Over 35% Intraday: Why It Happened

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax announced the publication of positive data from the company's Phase 2 HELP Study in the Journal of American College of Cardiology: Heart Failure

Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the year ended December 31, 2020 and provided a business update

Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) to present company overview at H.C. Wainwright Global Life Sciences Virtual Conference held March 9-10, 2021

Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) appoints June Almenoff, MD, PhD, Michael Davidson, MD, Delcan Doogan, MD, and Stuart Rich, MD to its Board.

Tenax Therapeutics, Inc. Expands Board of Directors

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) to host conf. call & live audio webcast on Jan 21, 2021, at 4:30 pm to discuss acquisition of PH Precision Med

Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med

Aclaris Therapeutics

Celyad

Gritstone Oncology Inc

Merus

Minerva Neurosciences

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV (NASDAQ: MRUS) announced a R&D collaboration and licensing agreement with large-cap pharma Eli Lilly And Co (NYSE: LLY) for developing up to three CD-engaging T-cell redirecting bispecific antibody therapies for oncology indications.

Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today

Tenax Therapeutics (TENX) stock is flying high on Tuesday after announcing it has acquired biotech company PH Precision Med. The post TENX Stock: 8 Things to Know About Tenax Therapeutics and PH Precision Med as Shares Rocket appeared first on InvestorPlace.

TENX Stock: 8 Things to Know About Tenax Therapeutics and PH Precision Med as Shares Rocket

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) acquires PH Precision Med (PHPM), adding imatinib to its pipeline. Stuart Rich, MD joins as CMO.

Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the third quarter 2020 and provided a business update

Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces HELP Study presented at American Heart Association (AHA) Scientific Sessions available Nov. 13th

Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) will host a virtual R&D webinar for analysts and investors on Wednesday, November 18, 2020 at 4:30 p.m. EST

Tenax Therapeutics to Host Virtual R&D Webinar with Scientific Experts Highlighting HELP Study Results

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces amendment to Orion License Agreement adding oral levosimendan.

Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces presentation of Phase 2 HELP Study at virtual meeting of HFSA on Saturday, Oct 3, 2020 @ 4:30 pm EDT

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.

Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update

Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) Announces $8MM Registered Direct and PIPE Offering with single healthcare-focused institutional investor

News for Tenax Therapeutics Stock (TENX)